The prognosis and clinical and pathological findings in 93 patients with breast cancer who had taken contraceptive steroids before diagnosis (study group) vwere compared with those in 93 control patients, also with breast cancer, matched for age and parity. The tumours in the women in the study group were found to have more favourable clinical and histological features than those in the control group. When only patients who had been treated by radical mastectomy were considered, those who had taken contraceptive steroids survived significantly longer even when differences in nodal state were taken into account. Significantly more patients in the study group had a family history of breast cancer.
Introduction
The effects of steroidal contraceptives on the incidence and prognosis of breast cancer are still uncertain. Oestrogens are carcinogenic in many species of animals, and Hertz' pointed out that since most compounds that are carcinogenic in man are also carcinogenic in animals the reverse is probably true. Large doses of oestrogens may cause regression of breast tumours in man, but small amounts may cause the growth rate to accelerate.2 In 1978, 54 million women were estimated to be using oral contraceptives.3 Several studies showed that women who have taken these products do not have an increased incidence of breast cancer,4-6 but controversy still remains over whether taking oral contraceptives affects the prognosis of the established disease. Most surgeons would advise their patients with recently diagnosed breast cancer not to take contraceptive steroids.
Spencer et a17 reported on 44 patients who had been taking oral contraceptives during the year preceding the diagnosis of breast cancer and compared these women with a control group of patients who had never taken oral contraceptives. They found no evidence that taking such products caused increased progression of disease. Since the preclinical phase of breast cancer may extend over many years, we carried out a further study of patients who had ever used steroidal contraceptives and report here our results.
Patients and methods
The study group 17 years), and only 14 were known to have been taking the products during the year before diagnosis. They were matched by age and parity with patients in a control group who presented with breast cancer at about the same time but had never taken oral contraceptive steroids. The related history, clinical findings, histological findings, and recurrence and survival rates in the two groups were compared.
The clinical stage of each tumour was ascertained from details recorded at the first outpatient visit. Most patients with early breast cancer were treated by radical mastectomy (table I), but 11 patients in each group were treated by wide excision and radiotherapy to the residual breast and node fields. This treatment had been chosen by random sample as part of a clinical trial.8 Seven patients in the study 
Results
Related history- Table II shows the clinical features of the patients. The two groups were closely similar, except that significantly more women in the study group had a family history of breast cancer (p < 0-05, X~,2= =4-18)- of treatments. Figure 1 shows the survival curves for the 65 patients in the study group and the 62 controls treated by radical mastectomy. Patients in the study group had significantly longer survival (p < 0 05, Z2= 4 15). As more patients in the control group had diseased axillary nodes we compared patients in each group according to stage. Figure  2 shows the survival curves of the 46 patients in the study group and the 33 controls with pathological stage I tumours (no nodal disease).
100I
Histological findings- Again those in the study group survived significantly longer (p < 0-04, X2=4-23). There was no significant difference between the survival of patients with pathological stage II tumours (nodal disease) when the study group (n = 19) was compared with the controls (n = 29), although the study group appeared to be faring better. All deaths were due to breast cancer. When recurrence rates were compared the study group again fared better than the controls but the differences did not reach significance. We therefore compared only those with early breast cancer who had undergone radical mastectomy rather than include the other categories
Discussion
In both the current study and the study of Spencer et all more women with breast cancer who had been taking contraceptive steroids had a family history of the disease than women in the control groups. This suggests several possibilities. One is that women with such a family history who are going to develop breast cancer some time during their life have the time of induction brought forward by taking contraceptive steroids. This would mean that in postmenopausal women there would subsequently be a dearth of breast cancer in those with a close family history who have taken such products. Alternatively, women with a family history of breast cancer may examine themselves more assiduously so that their tumour is discovered earlier. All epidemiological evidence points against a third hypothesis-namely, that contraceptive steroids actually cause cancer in these women-unless the converse is true-that is, that they prevent breast cancer in women without a family history. Lastly, both our findings and those of Spencer et all may have occurred by chance and be due either to the -small numbers studied or to some unknown bias. Indeed, no similar trend has been reported in other series. 4 Breast cancers occurring in women with a family history of the disease may behave differently from those in other women, and the above phenomenon may be related to this in some way. In women with a family history there is an increased tendency towards bilateral disease and a higher incidence of medullary and lobular tumours has been suggested.'0 Additionally, such patients have a 10-15% higher survival rate."t This raises the question whether the trend towards a lower recurrence rate and longer survival seen in the study group in the present series may have been mediated by the disproportionate number of women with a family history in this group.
Patients in the control group presented with larger and 1~ 776 BRITISH MEDICAL JOURNAL VOLUME 282 7 MARCH 1981 histologically more malignant tumours associated with increased axillary lymph-node disease. Women who take contraceptive steroids have more frequent medical examinations, and so possibly their tumours may be diagnosed at an earlier stage. Vessey et al, 6 however, reported that 95% of breast cancers in their study were initially discovered by the patient or her husband. This would seem to argue against detection bias as a reason for the higher proportion of patients with less advanced tumours in the study group. An alternative explanation is that taking contraceptive steroids has a beneficial biological effect on tumour growth and slows the natural progression of the disease. The significantly improved survival of patients in the study group who were treated by radical mastectomy may in part reflect the lower incidence of axillary node disease; but when differences in nodal disease were excluded by considering only patients with pathological stage I tumours the patients in the study group still survived longer. This again suggests that taking the products may have had some biologically beneficial effect on the tumour. Vessey et a16 studied over 700 women with newly diagnosed breast cancer and also found that women who had not taken oral contraceptives seemed to present with more advanced tumours and that this was reflected in the survival pattern. They also concluded that taking these products might have a beneficial effect on tumour growth and spread. There is certainly no evidence that taking oral contraceptives had any harmful effect, except possibly in patients with a close family history of breast cancer.
Introduction From 1973 to 1979 over 130 infants have been referred to Queen Mary's Hospital for Children, Carshalton, with a previously unreported condition of the legs. The condition is characterised by one leg, usually the right, lying in external rotation. This is often most obvious when the child is seated on the mother's knee. We present here details of the first 100 cases.
Patients and methods
All 100 children in this study were first seen and examined by Mr Geoffrey Walker, who recognised this condition about 10 years ago. Eighty-four cases were reviewed by the authors; the remaining 16 were seen by other doctors and reassessed by means of a questionnaire.
A birth and development history was taken in each case and a full orthopaedic examination made. We were particularly interested in the range of hip rotation, which was measured with the hips extended. A hip radiograph was available for all the children. Obstetric records were reviewed in 70 cases. Any child with a general disorder, such as cerebral palsy, or with clinical or radiological evidence of hip dysplasia was excluded from this study.
Results
Clinical signs and radiographs-The striking finding was that in 86 children (53 boys, 33 girls) the right leg was affected. Forty-six were firstborn. Thirty-five presented to the orthopaedic clinic at
